Coral Laboratories Ltd Stock Price Today (NSE: CORALAB)

Coral Laboratories Ltd

580.75+4.90 (+0.85%)
Market Closed

Fundamental Score

...

Coral Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Coral Laboratories Ltd share price today is 580.75, up +0.85% on NSE/BSE as of 22 September 2026. Coral Laboratories Ltd (CORALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 207.48 (Cr). The 52-week high for CORALAB share price is 679.00 and the 52-week low is 360.00. At a P/E ratio of 10.80x, CORALAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.98% and a debt-to-equity ratio of 0.02.

Coral Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
679.00
Low
545.00
Volume
1.9K
Change
+0.36%

Coral Laboratories Ltd share price chart: 0.36% return over the past month. 52-week high ₹679.00, 52-week low ₹360.00.

Coral Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
577.00577.00565.40575.85719.00 (Cr)
575.00579.00560.00570.05371.00 (Cr)
565.70594.00558.50578.40670.00 (Cr)
583.00593.00565.05570.902.54K (Cr)
573.30604.80564.75565.551.71K (Cr)
587.85587.95561.00585.002.43K (Cr)
570.00593.90560.00561.301.26K (Cr)
597.45597.50558.50580.001.91K (Cr)
594.95594.95566.00570.452.73K (Cr)
600.95600.95561.50570.651.37K (Cr)

Coral Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
638.75639.00558.50575.85-9.85%
574.35679.00540.00638.25+11.13%
618.00634.90547.95574.35-7.06%
526.00659.00475.00618.00+17.49%
427.70516.30411.10473.05+10.60%
392.45445.00373.10424.95+8.28%
434.00472.95360.00370.55-14.62%
436.60496.00420.10443.70+1.63%
458.95496.60415.00434.65-5.29%
494.90504.70429.00438.50-11.40%
511.90532.80482.50490.20-4.24%
478.00545.00478.00509.40+6.57%

Returns & Performance

Poor

Return on Equity (ROE)

7.98%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

11.15%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

15.91%

Average operating profit margin over 5 years

Dividend Yield

0.25%

Annual dividend as % of current share price

Coral Laboratories Ltd Valuation Check

Excellent

Price to Earnings (P/E)

10.80x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

71.51%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

110.19%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

57.37%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-2.31%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

3.60%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

3.60%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

135.86x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-4.83 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Coral Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of CORALAB across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Operating Margins (15.91%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 10.80 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (110.19%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (57.37%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (135.86x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 7.07)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (71.51%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (7.98%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Limited Growth History (-2.31% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (3.60% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (3.60% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Negative Free Cash Flow (₹-4.83 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Coral Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Coral Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
44.7/100
581
₹207.48
10.8
Average
7.98%
Poor
11.15%
Average
0.0
Excellent
3.60%
Average
-2.31%
Poor
0.25%
66.4/100
1862
₹446629.70
36.9
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9487
₹251405.50
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4958
₹167808.47
79.2
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112444.66
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1379
₹111394.44
33.0
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1944
₹104997.59
95.9
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1669
₹96034.26
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1139
₹95114.85
29.4
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2079
₹95062.27
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2270
₹93767.52
45.9
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Coral Laboratories Ltd PE Ratio History

Historical price-to-earnings ratio for CORALAB — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202444.19₹762.8517.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Coral Laboratories Ltd Dividend History

Annual cash dividends paid by CORALAB — dividend yield 0.25%

Financial YearDividends Paid (₹ Cr)
FY 20250.71 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Coral Laboratories Ltd Quarterly Performance

Latest quarterly metrics for CORALAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

57.37%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

110.19%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-2.31%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

3.60%

Compounded annual net profit growth over 5 years

Coral Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for CORALAB — calculated from daily price history

32RSI 14
Neutral — RSI 32

Momentum is balanced — neither overbought nor oversold.

SMA 50
596
▼ Price below SMA 50 — Short-term bearish
SMA 200
491
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Coral Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Coral Laboratories Ltd (CORALAB) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Coral Laboratories Ltd

Loading latest quarterly results...

About CORALAB (Coral Laboratories Ltd)

Coral Laboratories Ltd is a dynamic pharmaceutical company dedicated to developing, manufacturing, and marketing a broad spectrum of healthcare solutions. With a strong commitment ...to quality and innovation, Coralab focuses on creating accessible and affordable medicines that address diverse medical needs across various therapeutic areas. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the production of safe, effective, and reliable pharmaceutical products. Coralab continuously invests in research and development to stay at the forefront of pharmaceutical advancements and deliver innovative solutions that improve patient outcomes. Coralab's comprehensive product portfolio encompasses a wide range of therapeutic categories, catering to both acute and chronic conditions. These include formulations for managing infectious diseases, such as antibiotics and antifungals, as well as treatments for gastrointestinal disorders, pain management, and respiratory ailments. The company also offers a diverse selection of medications for cardiovascular health, diabetes management, and parasitic infections. With a focus on patient well-being, Coralab is committed to providing healthcare professionals and patients with a wide array of treatment options to enhance their quality of life. Coralab operates with a global perspective, serving markets in India and beyond. Through strategic partnerships and a robust distribution network, the company strives to make its pharmaceutical products accessible to patients worldwide. With a strong emphasis on ethical business practices and a customer-centric approach, Coralab aims to build lasting relationships with healthcare providers and stakeholders. Driven by a passion for improving global health, Coralab continues to expand its reach and impact, delivering high-quality pharmaceutical solutions to meet the evolving needs of patients around the world.

Company Details

Symbol:CORALAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Girish Madanlal Dhameja
Whole-Time Director
Ms. Sushma Shashi Kadkade
CFO & Non-Executive Director
Ms. Dhwani Karna Desai
Company Secretary & Compliance Officer

CORALAB Share Price: Frequently Asked Questions

What is the current share price of Coral Laboratories Ltd?

Coral Laboratories Ltd (CORALAB) trades at ₹580.75 on NSE and BSE. Market cap ₹207.48 (Cr). Educational data only.

What is the P/E ratio of Coral Laboratories Ltd?

Coral Laboratories Ltd has a P/E of 10.80x vs industry average 34.89x.

What is the Bull Run score for Coral Laboratories Ltd?

Coral Laboratories Ltd has a Bull Run score of 44.7/100 based on 25+ financial parameters.

Does Coral Laboratories Ltd pay dividends?

Coral Laboratories Ltd has a dividend yield of 0.25%. Past dividends don't guarantee future payments.

What is the ROE of Coral Laboratories Ltd?

Coral Laboratories Ltd has ROE of 7.98%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Coral Laboratories Ltd?

Coral Laboratories Ltd has debt-to-equity of 0.02.

Is Coral Laboratories Ltd a good investment?

Bull Run gives Coral Laboratories Ltd a score of 44.7/100. This is not investment advice — consult a SEBI-registered advisor.